A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELARM EFFICACY AND SAFETY STUDY WITH OPEN-LABEL EXTENSION OF BLU-5937 IN ADULT PARTICIPANTS WITH REFRACTORY CHRONIC COUGH INCLUDING UNEXPLAINED CHRONIC COUGH (CALM-2)

Registry ID

BUS-P3-02

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BELLUS HEALTH INC

Start date

2025-06-18

Last update

2025-02-11

Conditions

• CHRONIC COUGH

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NALBUPHINE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF PARTICIPANTS WITH REFRACTORY CHRONIC COUGH
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TAPLUCAINIUM INHALATION POWDER (NOC-110) IN ADULTS WITH REFRACTORY OR UNEXPLAINED CHRONIC COUGH

View on source registry